Drug Profile


Alternative Names: D 4809

Latest Information Update: 06 Oct 1997

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Celltech Group; Martinex R&D
  • Developer Martinex R&D
  • Class Antineoplastics
  • Mechanism of Action DNA inhibitors; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 06 Oct 1997 Discontinued-I for Cancer in Canada (Unknown route)
  • 22 Feb 1996 Phase-I clinical trials for Cancer in Canada (Unknown route)
  • 30 Nov 1995 D 4809 is now called dexifosfamide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top